Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The neurosurgeon at Northwestern Medicine discussed diagnostic approaches, evolving treatment strategies, and the importance of timely referral in managing peripheral nerve injuries. [WATCH TIME: 3 minutes]

Emerging Considerations in Peripheral Nerve Injury and Surgical Intervention: Kevin Swong, MD

Articles

The trial of the H₃ inverse agonist aims to evalute its ability to reduce cataplexy and improve symptoms in patients with narcolepsy type 1.

Phase 2 Study to Test Therapeutic Potential of Samelisant for Narcolepsy Type 1

New 5-year findings from the National RLS Opioid Registry presented at SLEEP 2025 highlight the long-term stability and dose trends of low-dose opioid therapy in patients with restless legs syndrome.

National RLS Registry Provides Long-Term Insights Into Opioid Use for Restless Legs Syndrome

Members from Nuvig Therapeutics discussed how NVG-2089 could improve the CIDP treatment landscape by offering IVIG-like efficacy with a better safety and administration profile. [WATCH TIME: 3 minutes]

Rationale Behind NVG-2089 as New Therapy for CIDP: Pamela Conley; Alan Glicklich, MD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

The neuroscientist and physician at Mount Sinai explored the role of sleep-dependent brain clearance in Alzheimer disease and how emerging research is challenging longstanding assumptions.

NeuroVoices: Andrew Varga, MD, on Debating Whether Brain Cleansing Prevents Alzheimer Disease

Senior Director, Patient Management, Care and Rehabilitation Research, National MS Society

The associate vice president of research at the National MS Society discussed a growing research initiative focused on defining and promoting evidence-based psychosocial wellness strategies for individuals with MS. [WATCH TIME: 6 minutes]

Expanding the Scope of Wellness Research in Multiple Sclerosis: Kathy Zackowski, PhD, OTR

Founder and Executive Director, Sumaira Foundation

The executive director of The Sumaira Foundation discussed a newly funded international trial assessing both approved and off-label NMOSD therapies to better inform treatment decisions and patient care. [WATCH TIME: 2 minutes]

Investigating Treatment Differences of Off-Label and Marketed Therapies for NMOSD: Sumaira Ahmed

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

SLEEP 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Treatment and Management of Mild-to-Moderate Multiple Sclerosis

Defining Mild Multiple Sclerosis

Video content above is prompted by the following:

How do you determine that the patient has mild or moderate MS?

Prognostic factors, imaging, and brain reserve in mild MS

In a panel discussion, multiple sclerosis (MS) experts Stephen Krieger, MD; Heidi Crayton, MD; Jacqueline Nicholas, MD, PhD; Patricia Coyle, MD, and Enrique Alvarez, MD, PhD, share their insights on current MS therapies, aspirations for guideline revisions, the importance of shared decision-making, and the role of medium-efficacy therapy in the management of mild-to-moderate MS.

Key opinion leaders provide insights into the prevalence and incidence of clinically isolated syndrome (CIS) within their clinical practice.

Presentation of Clinically Isolated Syndrome/First Attack of Multiple Sclerosis

The panelists explore diagnostic methods for differentiating between mild and moderate multiple sclerosis (MS) while also examining prognostic factors, the role of imaging, and the concept of brain reserve in mild MS cases.

Multiple sclerosis (MS) specialists discuss their observations regarding variations in MS presentation and progression among patients of Different Races and Ethnicities

Mild/Moderate Multiple Sclerosis in Patients of Different Races and Ethnicities

The expert panel examines early multiple sclerosis (MS) and patients with mild MS even in later stages of the disease, emphasizing crucial information to convey to patients throughout their journey; faculty also explore cases where disease-modifying therapies (DMTs) may not be utilized.

Conversations With Patients About Mild/Moderate Multiple Sclerosis

The key opinion leaders provide recommendations on the optimal frequency for evaluating disease progression in patients with mild to moderate MS, emphasizing effective monitoring methods and the most appropriate tools for best clinical practice.

Monitoring Patients With Mild/Moderate Multiple Sclerosis

The panel reflects on their experiences as practicing clinicians, emphasizing the significance of shared decision-making and actively listening to patients’ preferences regarding management of their MS. 

Shared Decision-Making for Patients With Mild/Moderate Multiple sclerosis

Multiple sclerosis (MS) treatment specialists discuss the challenges associated with the early use of high-efficacy therapy (HET) in patients with mild to moderate MS and delve into the broader debate surrounding the consistent use of HET for managing mild to moderate MS cases.

De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis

Key opinion leaders share their approach to treatment sequencing for patients with multiple sclerosis (MS), taking into account comorbidities such as cardiovascular diseases, risk of infection, liver damage, and cancer as well as considering factors like planned pregnancy or advanced age.

Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis

The panel explores factors influencing treatment adherence in multiple sclerosis (MS) patients and highlights the importance of shared decision-making in promoting and maintaining patient adherence to their prescribed therapy.

Treatment Adherence in Mild Multiple Sclerosis

Medical experts debate the concept of benign multiple sclerosis (MS), questioning whether this subtype truly exists or if it is a misnomer in the context of the disease's long-term progression and impact on patients.

Benign Multiple Sclerosis

The panel identifies and discusses the unmet needs of patients with mild to moderate multiple sclerosis (MS), highlighting areas where current treatment options and management strategies fall short in addressing the unique challenges faced by this patient population.

Diagnostic Uncertainty, Monitoring and Other Unmet Needs in Mild/Moderate Multiple Sclerosis

Key opinion leaders explore the impact of newly available biosimilars and generic biologics for managing multiple sclerosis (MS), discussing how these developments have altered patient access to treatments and the implications for the future of the MS treatment landscape.

Generics and Biosimilars in Multiple Sclerosis

Key opinion leaders examine the available data on Bruton tyrosine kinase (BTK) inhibitors to assess whether the evidence supports their efficacy as a treatment option for multiple sclerosis (MS).

Emerging Treatments in Mild/Moderate Multiple Sclerosis

In closing, the panel of experts in multiple sclerosis (MS) offer their insights and recommendations for clinicians, emphasizing best practices to optimize patient care and improve overall outcomes in the management of MS.

Final Thoughts on Caring for Patients With Mild/Moderate Multiple Sclerosis

Peer Exchange

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Defining Mild Multiple Sclerosis

EP: 1.Presentation of Clinically Isolated Syndrome/First Attack of Multiple Sclerosis

EP: 2.Defining Mild Multiple Sclerosis

EP: 3.Mild/Moderate Multiple Sclerosis in Patients of Different Races and Ethnicities

EP: 4.Conversations With Patients About Mild/Moderate Multiple Sclerosis

EP: 5.Monitoring Patients With Mild/Moderate Multiple Sclerosis

EP: 6.Shared Decision-Making for Patients With Mild/Moderate Multiple sclerosis

EP: 7.De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis

EP: 8.Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis

EP: 9.Treatment Adherence in Mild Multiple Sclerosis

EP: 10.Benign Multiple Sclerosis

EP: 11.Diagnostic Uncertainty, Monitoring and Other Unmet Needs in Mild/Moderate Multiple Sclerosis

EP: 12.Generics and Biosimilars in Multiple Sclerosis

EP: 13.Emerging Treatments in Mild/Moderate Multiple Sclerosis

EP: 14.Final Thoughts on Caring for Patients With Mild/Moderate Multiple Sclerosis

Newsletter